A comparison of the effects of lipoproteins of two progestogens used during cyclical hormone replacement therapy.
Lipoprotein levels were measured in 11 women who had been treated with 0.625 mg/day conjugated equine oestrogens with the addition of 0.15 mg/day DL-norgestrel for the last 12 days of each 28 day cycle for 48 wk. Treatment was then changed to an identical oestrogen regimen with dydrogesterone, 10 mg/day, as progestogen and monitoring continued for a further 24 wk. The oestrogen plus norgestrel regimen caused a significant reduction in low density lipoprotein (LDL) cholesterol levels. During the 24 wk after the change of therapy, levels of high density lipoprotein (HDL) increased significantly due to an increase in the HDL2 fraction and there was an upward trend in LDL cholesterol which did not attain statistical significance. We conclude that, when used in combination with conjugated equine oestrogens, changing from norgestrel, 0.15 mg/day, to dydrogesterone, 10 mg/day, does not lead to any significant improvement in lipoprotein profile.
Fletcher
C D
CD
Department of Biochemistry, Stobhill General Hospital, Glasgow, U.K.
Farish
E
E
Dagen
M M
MM
Hart
D M
DM
D008078:Cholesterol, LDL / Q000097:blood; D002979:Climacteric / Q000097:blood / Q000187:drug effects; D004359:Drug Therapy, Combination; D004394:Dydrogesterone / Q000008:administration & dosage / Q000009:adverse effects*; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage / Q000009:adverse effects*
D008078:Cholesterol, LDL; D004967:Estrogens; D008074:Lipoproteins; D009644:Norgestrel; D004394:Dydrogesterone